Abstract
Urinary albumin-to-creatinine ratio (uACR) measured on spot samples provides a convenient method to screen for, diagnose, stage and monitor chronic kidney disease (CKD),1 and change in albuminuria is proposed as a surrogate outcome for CKD progression in clinical trials.2 Sodium glucose co-transporter-2 (SGLT-2) inhibitors are increasingly used due to important effects on risk of cardiovascular disease and CKD progression.3 Under normoglycaemic and modest hyperglycaemic conditions, SGLT-2 inhibitors increase urinary glucose excretion to ∼50-80g/day, and to >100g/day in people with diabetes and glomerular hyperfiltration.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
